Gilead Sciences (GILD) announces a deal to purchase Pharmasset (VRUS) for $11B in a deal that is expected to close in Q1 and become accretive to Gilead's earnings starting in 2015. The $137/share offer price agreed upon by the firms marks an 89% premium to the closing price of Pharmassets on Friday
Shares of Inhibitex (INHX) and Vertex Pharmaceuticals (VRTX) show upward momentum following the news of Gilead's (GILD) blockbuster deal to buy Pharmasset (VRUS). Premarket: INHX +31%, VRTX +2%
More Stocks News
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com/